선택지 정리됨
임신성 융모성 질환 / 종양: 국가별 치료 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨희귀·유전 질환최종 확인 2026.06
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Surgery, single-agent chemotherapy, combination chemotherapy including EMA/CO and other regimens, intrathecal chemotherapy and/or brain radiation in selected metastatic contexts, salvage surgery in selected chemoresistant contexts, clinical trials[1]Standard option (per NCI PDQ)Low-risk GTN; high-risk metastatic GTN; stage I-IV PSTT/ETT; recurrent or chemoresistant GTN. · NCI states there are no randomized trials establishing superiority among commonly used high-risk regimens; EMA/CO is presented because it is commonly used, not because NCI declares it universally superior. Do not infer individual eligibility, dosing, or insurance coverage from this summary. Confidence/conflicts: High for U.S. evidence-framework categories; regimen superiority and individual treatment selection remain uncertain as the source states.
United Kingdom
- Methotrexate with folinic acid rescue, actinomycin D, EMA-CO, EP-EMA, TP/TE, intrathecal methotrexate in selected brain/high-risk contexts, pembrolizumab for chemotherapy-resistant situations, specialist-center chemotherapy[2]Standard option (per Cancer Research UK)hCG monitoring and risk score are described; no molecular biomarker specified in the fetched source; Low-risk invasive mole/choriocarcinoma; high-risk disease; ultra-high-risk disease; chemotherapy resistance; brain-spread/high-risk intrathecal context. · This is UK cancer information, not a NICE appraisal or individual commissioning decision. Pembrolizumab is described for rare chemotherapy-resistant situations; do not generalize to all GTN or imply automatic access. Confidence/conflicts: High for UK chemotherapy and specialist-center framework; NICE/commissioning specifics were not independently fetched in this finding.
- Monitoring/advisory follow-up, chemotherapy, surgery in selected cases, specialist GTD clinic assessment[3]Standard option (per Imperial College Healthcare NHS Trust)hCG monitoring implied by GTD service follow-up; no molecular biomarker specified in the fetched Imperial page; GTD follow-up/monitoring; cases needing additional treatment; specialist clinic assessment. · This source documents a specialist-service pathway and broad treatment categories, not specific chemotherapy regimens, eligibility, or national commissioning rules. Confidence/conflicts: High for the Charing Cross specialist-service and broad treatment pathway; regimen-level detail should use dedicated treatment sources.
출처
- National Cancer Institute — national cancer agency evidence summary · national cancer agency evidence summary
- Cancer Research UK — UK cancer information / specialist-center treatment information · UK cancer information / specialist-center treatment information
- Imperial College Healthcare NHS Trust — NHS specialist-service information · NHS specialist-service information
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026.06.
승인된 치료 너머
임상시험 및 신흥 선택지
환자가 거주하는 국가에서 아직 승인된 표준 치료가 아닌 선택지입니다 — 연구, 임상시험, 허가 외 사용, 담당 종양내과 의사가 먼저 언급하지 않을 수 있는 초기 근거입니다. 각 항목은 근거의 강도에 따라 구분됩니다. 여기에 실린 항목은 조사하고 의료진과 상의할 정보일 뿐, 효과가 입증되었거나 안전하거나 현재 이용 가능하다는 의미가 아닙니다. 임상 세부 내용은 영문이 정본입니다.
임상시험 진행 중
- Avelumab plus methotrexate; avelumab; domvanalimab plus zimberelimab with or without FOLFOX-4; French National Reference Centre registry/observational pathway임상시험 · NCT04396223임상시험Trial only (registry)European Union · Low-risk GTN first-line; chemo-resistant GTN; advanced rare-cancer platform including gestational trophoblastic tumor; national reference-centre GTD registry context. · Some records are interventional treatment studies; the French National Reference Centre record is registry/reference-centre context without an intervention listed. Trial participation and reference-centre registry inclusion should not be represented as approved access. Confidence/conflicts: High for France-site registry support; no EMA/ANSM/HAS access claim is made. ClinicalTrials.gov — clinical-trial registry
- Dactinomycin; methotrexate; leucovorin calcium; quality-of-life assessment임상시험 · NCT01535053임상시험Trial only (registry)Japan · Low-risk gestational trophoblastic neoplasia, including choriocarcinoma and FIGO stage I-III gestational trophoblastic tumor/hydatidiform mole contexts in the registry conditions. · The study is completed. Registry location text supports trial participation history in these countries, not current enrollment or local standard-of-care access. Confidence/conflicts: High for country-site and trial-context support; no regulator approval claim is made. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
- Pembrolizumab (Keytruda); pembrolizumab before second evacuation for post-molar GTN임상시험 · NCT04303884임상시험Trial only (registry)Korea · Chemo-resistant GTN for the South Korea record; post-molar GTN before second evacuation for the UK record. · Study statuses differ: unknown for the South Korea trial and recruiting for the UK trial. Immunotherapy should not be generalized to all GTN settings from these registry records. Confidence/conflicts: High for registry support; medium for current availability because one study status is unknown and neither source is a regulator/HTA document. ClinicalTrials.gov — clinical-trial registry
- Methotrexate, methotrexate plus actinomycin-D, actinomycin-D, hysteroscopic repeat curettage, etoposide/actinomycin D/methotrexate/vincristine/cyclophosphamide, paclitaxel/cisplatin/carboplatin, toripalimab plus actinomycin-D, camrelizumab plus apatinib, follow-up/chemotherapy strategy임상시험 · NCT01823315임상시험Trial only (registry)China · FIGO score/risk category as specified by individual registry records; no molecular biomarker specified; Low-risk GTN; low-risk postmolar GTN; high-risk gestational trophoblastic tumor; GTN FIGO score 5-6 or 7; recurrent resistant GTN; hydatidiform mole with lung nodule. · Several records have unknown overall status despite site text; one is completed, some are recruiting/active-not-recruiting. Trial records do not equal current standard of care or national approval. Confidence/conflicts: High for China-site registry support; no NMPA approval claim is made. ClinicalTrials.gov — clinical-trial registry
임상시험이나 초기 보고에 실렸다는 것은 해당 선택지가 연구되고 있다는 의미일 뿐, 효과가 있거나 특정 환자에게 안전하거나 현재 등록 가능하다는 뜻은 아닙니다. 어떤 선택지가 적합한지는 담당 종양내과 팀과 임상시험 팀이 함께 상의할 문제입니다. 최종 확인 2026.06.
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- What is the exact diagnosis and risk category: low-risk GTN, high-risk metastatic GTN, PSTT, ETT, recurrent, or chemoresistant disease?
- Is beta-hCG monitoring showing response, resistance, or recurrence?
- Is the treatment question single-agent chemotherapy, combination chemotherapy, surgery, brain-directed therapy, or a clinical trial?
- Which UK specialist GTD centre is coordinating care?